Literature DB >> 28066120

Eyelid and feet edema induced by pemetrexed.

Sarrah Kastalli1, Ons Charfi1, Rym Sahnoun1, Ghozlane Lakhoua1.   

Abstract

Pemetrexed is an anti-metabolite that targets multiple enzymes in folate pathway. The main toxicities associated with pemetrexed are asthenia, nausea, diarrhea, myelosuppression, and rash. Few cases of pemetrexed induced cutaneous adverse event have been reported, mainly periorbital-facial edema and edema of the limbs. We report a case of pemetrexed-induced edema of the eyelid and feet in a patient with adenocarcinoma of the lung.

Entities:  

Keywords:  Pemetrexed; pharmacovigilance; side effects

Mesh:

Substances:

Year:  2016        PMID: 28066120      PMCID: PMC5155483          DOI: 10.4103/0253-7613.194862

Source DB:  PubMed          Journal:  Indian J Pharmacol        ISSN: 0253-7613            Impact factor:   1.200


  4 in total

1.  Pemetrexed-induced fluid retention.

Authors:  Diogo Assed Bastos; Aknar Calabrich; Artur Katz
Journal:  J Thorac Oncol       Date:  2010-05       Impact factor: 15.609

2.  Pemetrexed-induced edema of the eyelid.

Authors:  Guillermo Guhl; Blanca Diaz-Ley; Javier Sanchez-Perez; Ulpino Jimenez; Amaro Garcia-Diez
Journal:  Lung Cancer       Date:  2010-05-21       Impact factor: 5.705

3.  Skin toxicities compromise prolonged pemetrexed treatment.

Authors:  Belen Eguia; Anne-Marie Ruppert; Julie Fillon; Armelle Lavolé; Valérie Gounant; Christelle Epaud; Bernard Milleron; Philippe Moguelet; Marie Wislez; Camille Frances; Jacques Cadranel
Journal:  J Thorac Oncol       Date:  2011-12       Impact factor: 15.609

4.  Severe periorbital edema secondary to STI571 (Gleevec).

Authors:  Bita Esmaeli; Victor G Prieto; Charles E Butler; Stella K Kim; M Amir Ahmadi; Hagop M Kantarjian; Moshe Talpaz
Journal:  Cancer       Date:  2002-08-15       Impact factor: 6.860

  4 in total
  1 in total

1.  Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.

Authors:  Eunhae Shin; Dong Hui Lim; Jisang Han; Do-Hyun Nam; Keunchil Park; Myung-Ju Ahn; Won Ki Kang; Jeeyun Lee; Jin Seok Ahn; Se-Hoon Lee; Jong-Mu Sun; Hyun Ae Jung; Tae-Young Chung
Journal:  BMC Ophthalmol       Date:  2020-01-09       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.